Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 2:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (66.7%)Phase 2
1 (33.3%)Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- NovaRx Corporation
- Registration Number
- NCT01279798
- Locations
- 🇺🇸
Innovative Research Center of California, San Diego, California, United States
Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung NeoplasmCarcinoma, Bronchogenic
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2010-07-29
- Lead Sponsor
- NovaRx Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT01058785
- Locations
- 🇺🇸
Hoag Cancer Center, Newport Beach, California, United States
🇺🇸Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD, and Janet Burroff MD APM, Metairie, Louisiana, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy
Phase 3
Completed
- Conditions
- Carcinoma Non-small Cell Lung Cancer Stage IIIBCarcinoma Non-small Cell Lung Cancer Stage IVLung NeoplasmCarcinoma Non-small Cell Lung Cancer Stage IIIA
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- NovaRx Corporation
- Target Recruit Count
- 532
- Registration Number
- NCT00676507
- Locations
- 🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Alaska Regional Hospital, Anchorage, Alaska, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
News
No news found